Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
Open accessAbstract
A heavily pretreated patient with triple negative breast cancer distinguished by cutaneous metastases received p53MVA vaccine in combination with pembrolizumab. Her cutaneous metastases regressed and after 2 cycles of therapy, a skin biopsy showed a complete pathological response. Systemic response was confirmed with restaging CT and bone scans. Activation of p53-specific T cell responses and elevation of multiple immune response genes in peripheral blood correlated with the rapid clinical response which lasted for 6 months after the initiation of combined therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hardwick's group conducted two early-phase clinical trials of MVAp53; MVAp53 induced CD8+ and CD4+ T cell responses in patients with refractory gastrointestinal cancer and ovarian cancer.
“Later in 2014 and 2018, Hardwick’s group conducted two early-phase clinical trials involving a modified vaccinia virus ankara vaccine encoding wtp53 (MVAp53 (253)). The studies showed that MVAp53 could induce CD8+ and CD4+ T cell responses in patients with refractory gastrointestinal cancer and ovarian cancer, respectively.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [592]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079 · see citing works
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · see citing works
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · see citing works
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477 · see citing works
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,394 · see citing works
Mutant p53: one name, many proteinsPreprint
Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,246 · see citing works
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · see citing works
Self-citationStack, E. C., Wang, C., Roman, K., & Hoyt, C. C. (2014) · Methods · doi:10.1016/j.ymeth.2014.08.016 · Cited by 779 · see citing works
Masuda, H., Baggerly, K., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric‐Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobágyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 753 · see citing works
Gene expression profiling in breast cancer: A clinical perspective
Arpino, G., Generali, D., Sapino, A., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.01.016 · Cited by 95 · see citing works
Hardwick, N. R., Carroll, M., Kaltcheva, T., Qian, D., Lim, D., Leong, L., Chu, P., Kim, J., Chao, J., Fakih, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3361 · Cited by 45 · see citing works
Self-citationAn MVA vaccine overcomes tolerance to human p53 in mice and humans
Song, G.-Y., Gibson, G., Haq, W., Huang, E. C., Srivasta, T., Hollstein, M., Daftarian, P. M., Wang, Z., Diamond, D. J., & Ellenhorn, J. D. I. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0270-3 · Cited by 28 · see citing works
Self-citationLiu, X., Peralta, E. A., Ellenhorn, J. D. I., et al. (2000) · PubMed · Cited by 24 · see citing works
Influence of p53 on anti-tumor immunity (Review)
Bueter, M., Gasser, M., Lebedeva, T., Bénichou, G., & Waaga-Gasser, A. M. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.2.519 · Cited by 17 · see citing works
Song, G.-Y., Srivastava, T., Ishizaki, H., et al. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.606248 · Cited by 15 · see citing works
Overcoming immunosuppression to enhance a p53MVA vaccine
Hardwick, N., Chung, V., Cristea, M., Ellenhorn, J. D., & Diamond, D. J. (2014) · OncoImmunology · doi:10.4161/21624011.2014.958949 · Cited by 11 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2709 · Cited by 66 · see citing works
Self-citation
- Authors
- Yuan, Y., Kos, F. J., He, T.-F., Yin, H. H., Li, M., Hardwick, N., Zurcher, K., Schmolze, D., Lee, P., Pillai, R. K., Chung, V., & Diamond, D. J.
- Affiliations
- City Of Hope National Medical Center (US)
- Corresponding author
- Diamond, Don J.
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-08-11
- Volume
- 6
- Issue
- 12
- Pages
- e1363138
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5706612
- OpenAlex
- W2744960134
- Cited by
- 23
- References
- 20
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 4 · 2020: 2 · 2019: 2 · 2018: 5
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Flight Attendant Medical Research Institute (042275)
- National Institutes of Health (25XS061)
- National Cancer Institute (K12CA001727, R21CA114889, P30CA033572)
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- triple-negative breast cancer, cutaneous metastasis, pembrolizumab, immune checkpoint inhibitors, cancer immunotherapy, pathological complete response, immune response genes, tumor regression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
